Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study
المؤلفون المشاركون
Chamarthi, Bindu
Roe, Erin D.
Raskin, Philip
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-04-28
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Background.
The concurrent use of a postprandial insulin sensitizing agent, such as bromocriptine-QR, a quick release formulation of bromocriptine, a dopamine D2 receptor agonist, may offer a strategy to improve glycemic control and limit/reduce insulin requirement in type 2 diabetes (T2DM) patients on high-dose insulin.
This open label pilot study evaluated this potential utility of bromocriptine-QR.
Methods.
Ten T2DM subjects on metformin (1-2 gm/day) and high-dose (TDID ≥ 65 U/day) basal-bolus insulin were enrolled to receive once daily (morning) bromocriptine-QR (1.6–4.8 mg/day) for 24 weeks.
Subjects with at least one postbaseline HbA 1c measurement ( N = 8 ) were analyzed for change from baseline HbA 1c , TDID, and postprandial glucose area under the curve of a four-hour mixed meal tolerance test (MMTT).
Results.
Compared to the baseline, average HbA 1c decreased 1.76% ( 9.74 ± 0.56 to 7.98 ± 0.36 , P = 0.01 ), average TDID decreased 27% ( 199 ± 33 to 147 ± 31 , P = 0.009 ), and MMTT AUC60–240 decreased 32% ( P = 0.04 ) over the treatment period.
The decline in HbA 1c and TDID was observed at 8 weeks and sustained over the remaining 16-week study duration.
Conclusion.
In this study, bromocriptine-QR therapy improved glycemic control and meal tolerance while reducing insulin requirement in T2DM subjects poorly controlled on high-dose insulin therapy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Roe, Erin D.& Chamarthi, Bindu& Raskin, Philip. 2015. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study. Journal of Diabetes Research،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1068013
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Roe, Erin D.…[et al.]. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study. Journal of Diabetes Research No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1068013
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Roe, Erin D.& Chamarthi, Bindu& Raskin, Philip. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study. Journal of Diabetes Research. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1068013
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1068013
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر